Boehringer Ingelheim founding sponsor of AHA's Cardiovascular-Kidney-Metabolic Health Initiative

Boehringer Ingelheim has announced its sponsorship of the American Heart Association's (AHA) Cardiovascular-Kidney-Metabolic Health (CKMH) Initiative. This four-year effort is designed to address the complex health threat of cardiovascular, renal and metabolic conditions through a person-centered approach to awareness, provider and patient education, and treatments for individuals with these diseases.

Why does this matter?

Affecting over one billion lives globally, cardiovascular, renal and metabolic diseases are among the leading causes of death worldwide. Boehringer Ingelheim is committed to reducing the burden and improving outcomes for people living with these diseases and their families. 

"Cardiovascular, kidney and metabolic diseases together represent one of the fastest growing health challenges of our time," says Carinne Brouillon, Head of Human Pharma at Boehringer Ingelheim. "Which is why we at Boehringer are delighted to support the American Heart Association with this critical initiative that will promote education and awareness as well as pinpoint new research – all critical areas of focus for us as a company, where we have rich history and knowledge."

• The initiative aligns with Boehringer Ingelheim's commitment to improve patient lives and to address gaps in clinical care through best-practice, guideline-focused solutions.
• The sponsorship fosters collaborations with healthcare professionals, academic institutions, patient organizations, policy makers, and digital health providers to facilitate the co-creation of evidence-based solutions. 
• The CKMH Initiative will address gaps in clinical care and support the development of guidance for early and holistic treatment in practice. The initiative will involve 150 hospitals and sites across the nation, reaching over 265,000 patients.

Cardiovascular, renal and metabolic diseases are interconnected, can co-exist and amplify one another, but their management is often fragmented. By supporting this initiative, Boehringer Ingelheim furthers its advocacy for an integrated approach to treatment and early prevention by diagnosing and managing these diseases as connected conditions.

More information about the CKMH Initiative can be found in the AHA press release here.

About Boehringer Ingelheim
Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma and Animal Health. Learn more at www.boehringer-ingelheim.com  

About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for a century. During 2024 - our Centennial year - we celebrate our rich 100-year history and accomplishments. As we forge ahead into our second century of bold discovery and impact our vision is to advance health and hope for everyone, everywhere. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.